{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:39:24Z","timestamp":1786649964631,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Inhaler corticosteroids (ICS) are the most commonly used antiinflammatory drugs in the treatment of asthma. Although systemic adverse effects are minimal, patients hesitate to use ICS for a long time because of corticophobia. There is no study evaluating corticophobia via Likert-type appendix among the asthmatic patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>In this study, it was aimed to evaluate the fears and beliefs about ICS in asthmatic patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and Methods:<\/jats:title>\n                    <jats:p>Between December 2017 and January 2018, 150 stable asthmatic patients were included in the study. Demographic data (age, education, smoking history, etc.) and asthma-related data (pulmonary function test, drug use) were recorded. The appendix of TOPICOP study applied to the patients with asthma which was composed of 10 questions (five questions about fear of ICS and five questions about beliefs of ICS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The rate of ICS maintain in stable asthmatic patients was found to be 66.6%. According to the survey results, 68% of the patients believed that ICS may lead to weight gain, 52% believed that ICS may lead to infection, 73% believed that ICS may pass into bloodstream, and 67.3% believed that ICS may damage the lungs. It was also found that 90.7% needed to be informed about ICS and 67.3% wanted to cut the ICS drug as soon as possible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We found that treatment adherence may increase, if physicians allocate more time to asthma patients to inform about ICS beneficial effects at the initiating of ICS treatment and control visits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njcp.njcp_341_19","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T05:53:33Z","timestamp":1597125213000},"page":"1033-1038","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of Corticophobia in Asthmatic Patients"],"prefix":"10.4103","volume":"23","author":[{"given":"HI","family":"Yakar","sequence":"first","affiliation":[{"name":"Department of Chest Disease, Faculty of Medicine, Tokat Gaziosmanpasa University, Tokat, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kanbay","sequence":"additional","affiliation":[{"name":"Department of Chest Disease, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"R2-20251006","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1378\/chest.113.3.587","article-title":"Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients","volume":"113","author":"Boulet","year":"1998","journal-title":"Chest"},{"key":"R3-20251006","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1046\/j.1365-2133.2000.03473.x","article-title":"Topical corticosteroid phobia in patients with atopic eczema","volume":"142","author":"Charman","year":"2000","journal-title":"Br J Dermatol"},{"key":"R4-20251006","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1080\/08035250600612298","article-title":"Steroid fears in children with eczema","volume":"95","author":"Hon","year":"2006","journal-title":"Acta Paediatr"},{"key":"R5-20251006","doi-asserted-by":"crossref","first-page":"e76493","DOI":"10.1371\/journal.pone.0076493","article-title":"TOPICOP: A new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents","volume":"8","author":"Moret","year":"2013","journal-title":"PLoS One"},{"key":"R6-20251006","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1471-2458-12-204","article-title":"Global asthma prevalence in adults: Findings from the cross-sectional world health survey","volume":"12","author":"To","year":"2012","journal-title":"BMC Public Health"},{"key":"R7-20251006","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rmed.2018.01.020","article-title":"Comorbidity, disease burden and mortality across age groups in a Swedish primary care asthma population: An epidemiological register study (PACEHR)","volume":"136","author":"Lisspers","year":"2018","journal-title":"Respir Med"},{"key":"R8-20251006","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1590\/S1807-59322009000800010","article-title":"Comorbidities in severe asthma: frequency of rhinitis, nasal polyposis, gastroesophageal reflux disease, vocal cord dysfunction and bronchiectasis","volume":"64","author":"Bisaccioni","year":"2009","journal-title":"Clinics (Sao Paulo)"},{"key":"R10-20251006","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: A systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"key":"R11-20251006","doi-asserted-by":"crossref","first-page":"80814","DOI":"10.1111\/j.1365-2133.2011.10449.x","article-title":"Topical corticosteroid phobia in atopic dermatitis: A study of its nature, origins and frequency","volume":"165","author":"Aubert-Wastiaux","year":"2011","journal-title":"Br J Dermatol"},{"key":"R12-20251006","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/adc.62.9.876","article-title":"Steroid scare","volume":"62","author":"David","year":"1987","journal-title":"Arch Dis Child"},{"key":"R13-20251006","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2500\/108854189778935773","article-title":"Prednisonephobia","volume":"10","author":"Patterson","year":"1989","journal-title":"Allergy Proc"},{"key":"R14-20251006","first-page":"163","article-title":"Steroid phobia among parents of asthmatic children: Myths and truth","volume":"9","author":"Zedan","year":"2010","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"R15-20251006","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/crj.12705","article-title":"Steroid phobia, Chinese medicine and asthma control","volume":"12","author":"Ip","year":"2018","journal-title":"Clin Respir J"},{"key":"R16-20251006","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1081\/JAS-100000028","article-title":"The magnitude of fear of adverse effects as a reason for nonparticipation in drug treatment: a short review","volume":"38","author":"Van Grunsven","year":"2001","journal-title":"J Asthma"},{"key":"R17-20251006","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.alit.2016.09.001","article-title":"Assessing usability of the \u201cAdherence Starts with Knowledge 20\u201d (ASK-20) appendix for Japanese adults with bronchial asthma receiving inhaled corticosteroids long term","volume":"66","author":"Atsuta","year":"2017","journal-title":"Allergol Int"},{"key":"R18-20251006","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1081-1206(10)60532-7","article-title":"Assessing the validity of self-reported medication adherence among inner-city asthmatic adults: The Medication Adherence Report Scale for Asthma","volume":"103","author":"Cohen","year":"2009","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_341_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:00:31Z","timestamp":1786647631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_341_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_341_19","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"2019-06-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}